Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy (NCT06736418)
A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy
🩺 Plain-English Summary (8th-Grade Level)
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather additional safety and efficacy data on 225Ac-ABD147 to determine the best dose and to understand how those doses affect the same types of patients' cancers explored enrolled in Phase 1a.
Who can join: Review the eligibility criteria below.
Location: Hoag Memorial Hospital Presbyterian — Newport Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- University of California, San Francisco — San Francisco, California
- University of California, Los Angeles — Santa Monica, California
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Sylvester Comprehensive Cancer Center, Univ of Miami — Miami, Florida
- Florida Cancer Specialists - Sarasota — Sarasota, Florida
- United Theranostics — Glen Burnie, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic - Rochester — Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center — New York, New York
- MD Anderson — Houston, Texas
- Huntsman Cancer Institute — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Small-Cell Lung Cancer (SCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.